Ocular Therapeutix officer plans sale of 3,035 shares
OCULAR THERAPEUTIX, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
OCULAR THERAPEUTIX, INC. (OCUL) received a Rule 144 notice from officer Peter Kazuo Kaiser covering a planned sale of company common stock. The notice lists 3,035 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an indicated aggregate value of $32,701.82. The shares relate to restricted stock vesting under a registered plan, with vesting and proposed sale timing noted in August 2026. The filing also reports that over the prior three months, Peter Kazuo Kaiser sold 2,967 shares of OCUL common stock for total proceeds of $24,333.55.
Key Figures
Key Terms
Rule 144 regulatory
restricted stock financial
registered plan regulatory
Executive Financial Services financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing disclose for OCUL?
What OCUL stock sales has Peter Kazuo Kaiser made in the last three months?
AI-generated analysis. How Rhea-AI works. Not financial advice.